Loading grant details…
Innovations to accelerate vaccine development and manufacture
| Funder | European Commission |
|---|---|
| Recipient Organization | European Vaccine Initiative E.V |
| Country | Germany |
| Start Date | Sep 01, 2021 |
| End Date | Feb 28, 2027 |
| Duration | 2,006 days |
| Number of Grantees | 41 |
| Roles | Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101007799 |
Grant Description
Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling persistent scientific bottlenecks in vaccine development and for de-risking and accelerating this process. To reach this aim the project is divided into four interlinked subtopics.
In Subtopic 1, artificial intelligence in combination with big data analysis and computational modelling will be used to build an open-access and cloud-based platform for in silico vaccine efficacy assessment and development.
Subtopic 2 will develop new and improved controlled human infection models (CHIM) against influenza, RSV and C. difficile that will enable early vaccine efficacy evaluation.
Subtopic 3 will contribute to the development of cell-based human in vitro 3D models that resemble the in vivo situation of an infection at the mucosa and more reliably predict immune protection.
These models will be combined with the development of related functional immune assays for clinically relevant (surrogate) endpoints.
Finally, Subtopic 4 will develop a modular one-stop computational platform for in silico modelling of vaccine bio-manufacturing and stability testing.
In parallel to the scientific-technical work, the partners will develop strategies and roadmaps for positioning the newly developed models in the regulatory framework and integrating them into pharmaceutical vaccine development.
The overall workplan is underpinned by horizontal activities on coordination/management and dissemination/communication, including data management and future sustainability.To achieve these ambitious objectives, Inno4Vacc has assembled a multidisciplinary consortium from academic and research institutions, industries, regulatory bodies, and vaccine R&D alliances.
This unique partnership brings together clinical, immunological, microbiological, systems biology, mathematical models, and regulatory expertise and includes world-leaders in each respective field.
All Grantees
Academisch Ziekenhuis Leiden; Sclavo Vaccines Association; Universita Degli Studi Di Siena; Medicines and Healthcare Products Regulatory Agency; Curevac Ag; Klinikum Der Universitaet Zu Koeln; Lunds Universitet; Stiftung Tieraerztliche Hochschule Hannover; Takeda Pharmaceuticals International Ag; Imperial College of Science Technology and Medicine; Forschungszentrum Julich Gmbh; Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel; Vismederi Srl; Inesc Tec - Instituto de Engenhariade Sistemas E Computadores, Tecnologia E Ciencia; Enpicom Bv; Academisch Ziekenhuis Groningen; Association Internationale de Standardisation Biologique Pour L'Europe(Iabs-Eu); Glaxosmithkline Biologicals Sa; Pharmalex Belgium; Mct Bioseparation Aps; Stichting Centre for Human Drug Research; Insilico Biotechnology Ag; Rijksinstituut Voor Volksgezondheid En Milieu; Helmholtz-Zentrum Fur Infektionsforschung Gmbh; Universitetet I Oslo; Danmarks Tekniske Universitet; The University of Nottingham; European Vaccine Initiative E.V; The Chancellor, Masters and Scholars of the University of Oxford; Sanofi Pasteur Sa; Universiteit Utrecht; Eberhard Karls Universitaet Tuebingen; University College London; Viroclinics Biosciences Bv; Julius-Maximilians-Universitat Wurzburg; Nova Id Fct - Associacao Para A Inovacao E Desenvolvimento Da Fct; Goeteborgs Universitet; Universitetet I Bergen; Sciensano; 2-Control Aps; Universitatsklinikum Jena
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
